Trial Profile
A Multicenter Randomized Phase II Study Evaluating The Activity And Tolerability Of Three Different Combinations Of Docetaxel (Taxotere) And Irinotecan (Campto) As Second Line Therapy For Recurrent Or Metastatic Non Small Cell Lung Cancer (NSCLS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2006
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Irinotecan (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 03 Nov 2006 Status change
- 01 Nov 2005 New trial record.